Search - tctmd.com

Displaying 201 - 220 of 313

Sort: Relevancy | Date

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Pneumonia in HF Patients Is Common, Lethal, and Preventable

L.A. McKeown

April 19, 2021

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Daily News

Cardiometabolic Diseases Contribute to Bulk of COVID-19 Hospitalizations

Todd Neale

March 04, 2021

News Opinion CV Team Dispatch

March 2021 News Roundup

L.A. McKeown

March 01, 2021

News Daily News

High Glycemic Index Diets Linked to CVD and Mortality

Michael O'Riordan

February 24, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Fracking, Other Natural Gas Activity Linked to Hospitalizations for HF Patients

L.A. McKeown

December 07, 2020

News Conference News AHA 2020

One in Five Patients Admitted With COVID-19 Die in the Hospital

Michael O'Riordan

November 20, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

Todd Neale

November 16, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

More HF Readmissions Among Black People From Deprived Neighborhoods

News Conference News HFSA 2020

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

Advertisement

FDA Approves Dapagliflozin for CKD Patients

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Pneumonia in HF Patients Is Common, Lethal, and Preventable

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Cardiometabolic Diseases Contribute to Bulk of COVID-19 Hospitalizations

March 2021 News Roundup

High Glycemic Index Diets Linked to CVD and Mortality

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Fracking, Other Natural Gas Activity Linked to Hospitalizations for HF Patients

One in Five Patients Admitted With COVID-19 Die in the Hospital

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

More HF Readmissions Among Black People From Deprived Neighborhoods

TCTMD’s Top 10 Most Popular Stories for September 2020

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content